Bamco Inc. NY bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) in the third quarter, Holdings Channel reports. The fund bought 31,000 shares of the company’s stock, valued at approximately $3,542,000.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Driehaus Capital Management LLC boosted its position in Vaxcyte by 3.6% during the second quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company’s stock worth $146,093,000 after acquiring an additional 66,940 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Vaxcyte by 47.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after purchasing an additional 419,600 shares during the last quarter. Maverick Capital Ltd. grew its position in shares of Vaxcyte by 41.9% in the third quarter. Maverick Capital Ltd. now owns 976,249 shares of the company’s stock valued at $111,556,000 after purchasing an additional 288,341 shares in the last quarter. Novo Holdings A S increased its holdings in shares of Vaxcyte by 12.4% in the second quarter. Novo Holdings A S now owns 950,000 shares of the company’s stock valued at $71,734,000 after purchasing an additional 105,000 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Vaxcyte by 14.3% during the second quarter. American Century Companies Inc. now owns 527,594 shares of the company’s stock worth $39,839,000 after buying an additional 65,870 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.
Insider Activity at Vaxcyte
In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,429,294.37. The trade was a 31.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 7,098 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $109.21, for a total transaction of $775,172.58. Following the sale, the chief executive officer now directly owns 138,581 shares in the company, valued at $15,134,431.01. This represents a 4.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,464 shares of company stock worth $11,924,596. 3.10% of the stock is currently owned by company insiders.
Vaxcyte Stock Performance
Vaxcyte (NASDAQ:PCVX – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the business posted ($0.91) earnings per share. Equities analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.
Wall Street Analysts Forecast Growth
PCVX has been the subject of several analyst reports. Leerink Partners upped their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Bank of America lifted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. BTIG Research lifted their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $147.50.
View Our Latest Report on PCVX
Vaxcyte Company Profile
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
- Five stocks we like better than Vaxcyte
- Bank Stocks – Best Bank Stocks to Invest In
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Consumer Discretionary Stocks Explained
- Netflix Is On Track To Hit $1,000 By Christmas
- How to Capture the Benefits of Dividend Increases
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX – Free Report).
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.